Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: R-1549, Antisoma/Roche.

Pei Xiang Xing¹

¹Austin Research Institute, Studley Rd, Heidelberg, Vic 3084, Australia. px.xing@ari.unimelb.edu.au

Current Opinion in Molecular Therapeutics

|November 7, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival.

Cellular immunology·2011

Same author

Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.

Experimental hematology·2009

Same author

PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

The Journal of clinical investigation·2009

Same author

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma.

Expert review of anticancer therapy·2006

Same author

The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene.

Journal of immunology (Baltimore, Md. : 1950)·2006

Same author

MDX-060. Medarex.

Current opinion in investigational drugs (London, England : 2000)·2005

R-1549, a novel antibody treatment, is being developed for ovarian and gastric cancers. A phase III clinical trial for ovarian cancer treatment was completed in July 2003.

Area of Science:

Oncology
Immunotherapy
Radiopharmaceutical Therapy

Background:

R-1549 (pemtumomab) is a murine monoclonal antibody targeting the cancer antigen PEM.
It is radiolabeled with yttrium-90 for therapeutic use.
Antisoma and Roche are developing R-1549 for ovarian and gastric cancer treatment.

Purpose of the Study:

To evaluate R-1549 as a potential treatment for ovarian and gastric cancers.

Main Methods:

Development of R-1549, a murine monoclonal antibody (HMFG1).
Radiolabeling of R-1549 with yttrium-90.
Initiation and enrollment for a phase III clinical trial in ovarian cancer.

Main Results:

Enrollment for the phase III ovarian cancer trial was completed in July 2003.

Related Experiment Videos

Conclusions:

R-1549 shows promise as a targeted radiopharmaceutical therapy for ovarian and gastric malignancies.